Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Proof of Concept, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery

NCT03941483 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT03941483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03941483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Proof of Concept, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
November 1, 2019
Completion date
October 20, 2021
Enrollment
351 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury (aki)